Henlius Biotech H1 2025 Financial ReportHenlius BiotechHenlius reports H1 2025 results: overseas profits soar 200%, global product expansion, and innovation pipeline growth, driving ‘Globalization 2.0’ and next-gen therapies worldwide.
Hansoh Pharma H1 2025 Financial ReportHansoh PharmaHansoh Pharma’s 2025 interim report highlights strong growth, innovation-driven transformation, and a robust global pipeline, setting a new benchmark for Chinese biopharma.
Hengrui H1 2025 Financial ReportHengrui PharmaceuticalsHengrui Medicine’s 2025 half-year report shows 60% revenue from innovative drugs and $12B potential overseas deals, highlighting strong growth, R&D depth, and global expansion.
Rongchang Biopharma H1 2025 Financial ReportRongchang BiopharmaRongchang Biopharma’s 2025 interim report shows 48% revenue growth, rising margins, reduced losses, and accelerated global BD deals, highlighting strong R&D, commercialization, and international expansion momentum.
Dizal Pharma H1 2025 Financial ReportDizal PharmaDizal Pharma reports its strongest half-year results in history, achieving first commercialization profit, accelerating R&D, and advancing global expansion with FDA-approved therapies.
BeOne(BeiGene) Q2 2025 Interim Financial ReportBeiGeneBeiGene reported a net profit of 450 million yuan for H1 2025, marking its first interim profit since A-share listing. Strong product sales and revised revenue and margin forecasts signal sustainable growth.
Chemical Industry Facing Order DroughtChinese Pharmaceutical MarketChina's recent trade data reveals a concerning trend: September imports rose just 0.3% while exports dropped 2.4%, marking the lowest growth rate this year. Experts attribute the decline to a weakening global economy and domestic consumption challenges, intensifying deflation risks.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
